Imunon Q2 FY26 net loss widens to $2.8 million

Reuters2026/08/11 12:04

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Imunon posted a GAAP net loss of $2.8 million, or $0.54 a share, for Q2 2026 versus a $2.7 million loss a year earlier.
R&D expense rose 22.73% to $1.5 million, while G&A expense fell 13.33% to $1.3 million.
First-half GAAP net loss widened to $7.1 million, or $1.38 a share, from $6.8 million a year earlier.
Cash and cash equivalents slipped to $6.9 million at June 30, 2026; operating cash burn increased to $7 million in the first half.
OVATION 3 Phase 3 enrollment continues to outpace forecasts; completion is targeted for the first half of 2029 following Phase 2 survival results.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Imunon Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608110800PRIMZONEFULLFEED9807375) on August 11, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Imunon Q2 FY26 net loss widens to $2.8 million

You may also like

Crypto prices